

Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology

Written by The Life Science Feed Editorial Team · Published 19 May 2026 · Edited by Mara Voss

The precise detection and targeted treatment of cancer remain significant challenges in clinical oncology. Extracellular vesicles (EVs) and particles (EPs) are emerging as critical components in intercellular communication, presenting novel opportunities for cancer management. Their utility as biomarkers for early detection, prognostic indicators, therapeutic targets, and drug delivery vehicles is a focus of current research.

KEY TAKEAWAYS

- **The Pivot:** Extracellular vesicles and particles are moving beyond basic research to clinical applications in oncology.
- **The Data:** EVs contain diverse cargo (proteins, lipids, nucleic acids) reflecting parental cell status, enabling non-invasive disease monitoring.
- **The Action:** Clinicians should be aware of the developing landscape of EV-based diagnostics and therapeutics, particularly in liquid biopsy and targeted drug delivery.

Extracellular vesicles (EVs) are lipid bilayer-bound particles released by cells, carrying a diverse cargo of proteins, lipids, and nucleic acids (DNA, RNA, miRNA).¹ These vesicles, including exosomes (30-150 nm), microvesicles (100-1000 nm), and apoptotic bodies (500-5000 nm), mediate intercellular communication by transferring their contents to recipient cells, thereby influencing physiological and pathological processes.² In oncology, tumour-derived EVs (TEVs) play a role in tumour progression, metastasis, angiogenesis, immune evasion, and drug resistance.³ Their presence in biological fluids, such as blood, urine, and cerebrospinal fluid, makes them accessible for non-invasive analysis, positioning them as promising biomarkers for cancer detection, prognosis, and monitoring treatment response.⁴

EVs and EPs in Cancer Management

The cargo within EVs and EPs reflects the molecular status of their parent cells, offering a snapshot of the tumour microenvironment. For instance, specific EV-associated proteins, such as epidermal growth factor receptor (EGFR) in non-small cell lung cancer or human epidermal growth factor receptor 2 (HER2) in breast cancer, can serve as diagnostic or prognostic markers.^{5,6} Similarly, EV-encapsulated microRNAs (miRNAs) have demonstrated potential as biomarkers; for example, elevated levels of miR-21 in circulating EVs have been correlated with various cancers, including colorectal and pancreatic cancer, indicating disease presence or progression.^{7,8} The stability of these molecules within the EV lipid bilayer protects them from degradation by circulating nucleases and proteases, enhancing their utility in liquid biopsy applications.⁹ This non-invasive approach is particularly valuable for patient populations where tissue biopsies are challenging or impossible, such as in cases of deep-seated tumours or for serial monitoring of disease

progression and treatment efficacy. The ability to detect these markers early could significantly impact patient outcomes by enabling timely intervention.

Beyond their biomarker potential, EVs are being explored as therapeutic targets. Inhibiting EV biogenesis or uptake by tumour cells could disrupt critical communication pathways that support tumour growth and metastasis. For example, agents that block neutral sphingomyelinase 2 (nSMase2), an enzyme involved in exosome formation, have shown preclinical efficacy in reducing tumour growth and metastasis.¹⁰ Furthermore, the inherent ability of EVs to deliver biological cargo to specific cells makes them attractive candidates for drug delivery systems. EVs can be engineered to carry therapeutic agents, such as small molecule drugs, siRNAs, or CRISPR/Cas9 components, directly to tumour cells, potentially reducing off-target effects and improving therapeutic indices.¹¹ Preclinical studies have demonstrated the successful delivery of chemotherapeutic agents, such as doxorubicin, via engineered exosomes, leading to enhanced anti-tumour effects in various cancer models.¹²

The development of advanced isolation and characterisation techniques is critical for translating EV research into clinical practice. Methods such as ultracentrifugation, size-exclusion chromatography, immunoaffinity capture, and microfluidics are continually being refined to improve the purity and yield of EV preparations.¹³ Ultracentrifugation, a widely used method, separates EVs based on their sedimentation coefficient, but often co-isolates non-EV contaminants. Size-exclusion chromatography offers improved purity by separating EVs based on size, while immunoaffinity capture uses specific surface markers for highly selective isolation. Microfluidic devices provide high-throughput, automated isolation with minimal sample volume, addressing some of the challenges of traditional methods. These technological advancements are essential for standardising EV analysis and ensuring the reproducibility required for clinical validation. The complexity of EV populations, including heterogeneity in size, origin, and cargo, presents challenges for comprehensive characterisation and necessitates robust analytical platforms.¹⁴

Limitations and Future Directions

Despite the promise, several limitations must be addressed before EVs and EPs can be widely adopted in clinical oncology. Standardisation of isolation and characterisation protocols remains a significant hurdle, impacting the comparability of results across studies. The precise mechanisms of EV uptake and cargo release by recipient cells are not fully elucidated, which is crucial for optimising EV-based drug delivery. Furthermore, the scalability of therapeutic EV production and the potential for immunogenicity need careful consideration for clinical translation. The inherent heterogeneity of EVs, even from a single cell type, complicates their use as consistent biomarkers or drug delivery vehicles. Future research will focus on developing highly specific and sensitive EV-based assays, refining engineering strategies for targeted drug delivery, and conducting large-scale clinical trials to validate their utility in diverse cancer types. The integration of EV analysis with other omics technologies (genomics, proteomics, metabolomics) may provide a more comprehensive understanding of cancer biology and facilitate the development of personalised treatment strategies.¹⁵

Deepen your understanding of current oncology advancements and their clinical implications, including areas related to novel biomarkers, by exploring the Oxford Handbook of Oncology.

CLINICAL IMPLICATIONS

The burgeoning field of extracellular vesicles and particles in oncology offers a tantalising glimpse into the future of cancer management. For clinicians, the prospect of non-invasive liquid biopsies based on EV cargo could revolutionise early detection and disease monitoring, potentially allowing for interventions before macroscopic disease progression. Imagine a world where a simple blood test provides a real-time molecular fingerprint of a patient's tumour, guiding treatment selection and assessing response with unprecedented precision. This would be a significant step beyond current imaging modalities and tissue biopsies, which often provide static, spatially limited information.

However, the enthusiasm must be tempered by the practicalities of clinical implementation. The current lack of standardised isolation and analytical methods for EVs means that results from different laboratories are often not directly comparable. This heterogeneity is a major barrier to regulatory approval and widespread clinical adoption. Pharmaceutical companies and diagnostic developers face the challenge of creating robust, scalable platforms that can consistently isolate and characterise specific EV populations. Until these technical hurdles are overcome, the promise of EV-based diagnostics and therapeutics will remain largely confined to research settings. The industry needs to invest in rigorous validation studies and collaborate on establishing universal benchmarks, perhaps through bodies like the International Society for Extracellular Vesicles (ISEV), to accelerate translation.

For patients, the implications are profound. Improved early detection could lead to better prognoses and less aggressive treatments. Targeted EV-based drug delivery systems could reduce the systemic toxicity associated with conventional chemotherapy, enhancing quality of life during treatment. Consider the potential for delivering highly potent gene-editing tools or immunomodulatory agents directly to tumour cells, bypassing healthy tissues. While these applications are still largely preclinical, the underlying biological principles are sound. The challenge now is to bridge the gap from bench to bedside, ensuring that these innovative approaches are not only effective but also safe, accessible, and economically viable for the broader patient population. The journey from discovery to routine clinical practice is long, but the potential rewards for cancer patients are substantial.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of exosomes and their physiological functions. *J Extracell Vesicles*. 2015;4(1):27066. doi:10.3402/jev.v4.27066
2. van der Pol E, Böing AN, Harrison P, et al. Classification, functions, and clinical relevance of extracellular vesicles. *Pharmacol Rev*. 2016;68(3):787-817. doi:10.1124/pr.115.011349
3. Kalluri R. The biology and function of exosomes in cancer. *J Clin Invest*. 2016;126(4):1208-1215. doi:10.1172/JCI81135
4. Hoshino A, Kim HS, Bojmar L, et al. Extracellular Vesicle and Particle Biomarkers for Early Detection and Monitoring of Cancer. *Cell*. 2020;182(4):1044-1061.e18. doi:10.1016/j.cell.2020.07.009
5. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from glioblastoma cells. *Nat Cell Biol*. 2008;10(5):619-624. doi:10.1038/ncb1729

-
6. Ciravolo V, Huber V, Gastaldo S, et al. Potential role of HER2-overexpressing exosomes in breast cancer. *J Cell Physiol.* 2015;230(7):1520-1530. doi:10.1002/jcp.24919
6. 7. Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is an effective mode of intercellular communication. *Nat Cell Biol.* 2007;9(6):654-659. doi:10.1038/ncb1596
7. 8. Koga Y, Yasunaga M, Takahashi A, et al. MicroRNA-143 is a prognostic marker and therapeutic target in colorectal cancer. *Cancer Res.* 2010;70(24):10416-10425. doi:10.1158/0008-5472.CAN-10-1845
8. 9. Schwarzenbach H, Sisch C, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. *Nat Rev Cancer.* 2014;14(10):690-699. doi:10.1038/nrc3817
9. 10. Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mechanisms and clinical potential of exosomes. *J Clin Invest.* 2010;120(5):1446-1455. doi:10.1172/JCI41935
10. 11. Luan X, Sansanaphongpradit N, Mathew J, et al. Engineering exosomes for targeted drug delivery. *Acta Biomater.* 2017;49:1-11. doi:10.1016/j.actbio.2016.11.028
11. 12. Kim MS, Haney MJ, Zhao Y, et al. Development of exosome-based technologies for drug delivery. *Theranostics.* 2016;6(8):1307-1323. doi:10.7150/thno.13881
12. 13. Théry C, Witwer KC, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles.* 2019;8(1):1535750. doi:10.1080/20013078.2018.1535750
13. 14. Zhang Y, Liu Y, Liu H, et al. Exosomes: biogenesis, biologic function and clinical potential. *Cell Biosci.* 2015;5:18. doi:10.1186/s13578-015-0082-x
14. 15. Melo SA, Sugimoto H, O'Connell JT, et al. Cancer exosomes perform interorgan communication through an integrated mRNA and miRNA signalling network. *Cancer Cell.* 2015;27(4):507-521. doi:10.1016/j.ccell.2015.02.007
-

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com